A Study to see the efficacy of Asgandh (Withania Somnifera) in Primary Hypothyroidism

Evaluation of the add on effect of Asgandh (Withania somnifera) with Levothyroxine Sodium in Primary Hypothyroidism- A Randomized standard controlled Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/023913

Enrollment

Registered

2020-03-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E039- Hypothyroidism, unspecified

Interventions

Intervention1: Asgandh (Withania somnifera): Drug dosage: Safoof Asgandh: 1 gm twice a day Form: Capsule Route of administration: Orally Duration of therapy: 60 days Control Intervention1: Levothyroxi

Eligibility

Inclusion criteria

Inclusion criteria: 1 Clinically diagnosed and know cases of primary hypothyroidism with or without treatment. 2 Patients having TSH level range between 10-20 mu/I. 3 Patients who are willing to give consent.

Exclusion criteria

Exclusion criteria: 1 Subjects with clinically significant renal, hepatic, endocrine (including diabetes mellitus), cardiac, pulmonary, pancreatic, neurologic, hematologic disorder 2 Hyperthyroidism 3 Pregnant and lactating mothers 4 Patients who fail to give consent

Design outcomes

Primary

Measure	Time frame
Change in objective parametersTimepoint: 60 Days	—

Secondary

Measure	Time frame
Fatigue Cold intolerance Constipation Weight gainTimepoint: Before treatment, 15th day, 30th day, 45th day, after treatment	—

Countries

India

Contacts

Public ContactMohd Khalid

Luqman Unani Medical College Hospital and Research Centre

drqudtathullah@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026